Anuh Pharma Limited (BOM:506260)
India
· Delayed Price · Currency is INR 77.84
+0.65 (0.84%)
At close: Mar 9, 2026
Anuh Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 7,677 | 6,615 | 6,470 | 5,275 | 4,866 | 4,320 | Upgrade
|
| Revenue Growth (YoY) | 22.38% | 2.24% | 22.66% | 8.39% | 12.66% | 40.72% | Upgrade
|
| Cost of Revenue | 6,042 | 5,067 | 4,914 | 4,075 | 3,809 | 3,329 | Upgrade
|
| Gross Profit | 1,634 | 1,548 | 1,556 | 1,200 | 1,057 | 990.23 | Upgrade
|
| Selling, General & Admin | 282.52 | 244.91 | 206.91 | 180.15 | 156.67 | 147.57 | Upgrade
|
| Other Operating Expenses | 736.67 | 655.21 | 594.25 | 486.85 | 417.13 | 394.33 | Upgrade
|
| Operating Expenses | 1,142 | 998.53 | 887.24 | 762.31 | 691.69 | 694.83 | Upgrade
|
| Operating Income | 492.89 | 549.51 | 668.73 | 437.21 | 365.35 | 295.4 | Upgrade
|
| Interest Expense | -4 | -6.19 | -3.54 | -2.18 | -9.61 | -14.95 | Upgrade
|
| Interest & Investment Income | 14.8 | 14.8 | 12.68 | 14.98 | 23.98 | 21.08 | Upgrade
|
| Currency Exchange Gain (Loss) | -27.81 | -27.81 | -2.86 | -21.46 | -16.49 | 3.02 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.48 | 1.29 | 1.08 | 2.63 | 1.01 | 0.85 | Upgrade
|
| EBT Excluding Unusual Items | 481.35 | 531.59 | 676.1 | 431.17 | 364.24 | 305.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 78.3 | 78.3 | 107.21 | 43.39 | 26.37 | 80.44 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.17 | 0.17 | -0.22 | 0.15 | 0.62 | -0.32 | Upgrade
|
| Pretax Income | 559.82 | 610.05 | 783.1 | 474.7 | 391.22 | 385.51 | Upgrade
|
| Income Tax Expense | 141.6 | 136.53 | 182.52 | 112.91 | 85.61 | 101.15 | Upgrade
|
| Net Income | 418.22 | 473.52 | 600.58 | 361.8 | 305.61 | 284.36 | Upgrade
|
| Net Income to Common | 418.22 | 473.52 | 600.58 | 361.8 | 305.61 | 284.36 | Upgrade
|
| Net Income Growth | -16.78% | -21.16% | 66.00% | 18.38% | 7.47% | 98.78% | Upgrade
|
| Shares Outstanding (Basic) | 100 | 100 | 100 | 100 | 100 | 100 | Upgrade
|
| Shares Outstanding (Diluted) | 100 | 100 | 100 | 100 | 100 | 100 | Upgrade
|
| EPS (Basic) | 4.17 | 4.72 | 5.99 | 3.61 | 3.05 | 2.84 | Upgrade
|
| EPS (Diluted) | 4.17 | 4.72 | 5.99 | 3.61 | 3.05 | 2.84 | Upgrade
|
| EPS Growth | -16.71% | -21.16% | 66.00% | 18.38% | 7.47% | 98.78% | Upgrade
|
| Free Cash Flow | - | 169.79 | 79.09 | 523.52 | 272.49 | -248.89 | Upgrade
|
| Free Cash Flow Per Share | - | 1.69 | 0.79 | 5.22 | 2.72 | -2.48 | Upgrade
|
| Dividend Per Share | - | 0.750 | 1.250 | 1.000 | 0.875 | 0.750 | Upgrade
|
| Dividend Growth | - | -40.00% | 25.00% | 14.29% | 16.67% | 9.09% | Upgrade
|
| Gross Margin | 21.29% | 23.40% | 24.05% | 22.74% | 21.72% | 22.92% | Upgrade
|
| Operating Margin | 6.42% | 8.31% | 10.34% | 8.29% | 7.51% | 6.84% | Upgrade
|
| Profit Margin | 5.45% | 7.16% | 9.28% | 6.86% | 6.28% | 6.58% | Upgrade
|
| Free Cash Flow Margin | - | 2.57% | 1.22% | 9.93% | 5.60% | -5.76% | Upgrade
|
| EBITDA | 576.28 | 631.74 | 749.41 | 531.16 | 481.55 | 440.63 | Upgrade
|
| EBITDA Margin | 7.51% | 9.55% | 11.58% | 10.07% | 9.89% | 10.20% | Upgrade
|
| D&A For EBITDA | 83.39 | 82.23 | 80.68 | 93.95 | 116.2 | 145.23 | Upgrade
|
| EBIT | 492.89 | 549.51 | 668.73 | 437.21 | 365.35 | 295.4 | Upgrade
|
| EBIT Margin | 6.42% | 8.31% | 10.34% | 8.29% | 7.51% | 6.84% | Upgrade
|
| Effective Tax Rate | 25.29% | 22.38% | 23.31% | 23.79% | 21.88% | 26.24% | Upgrade
|
| Revenue as Reported | 7,776 | 6,710 | 6,591 | 5,336 | 4,918 | 4,425 | Upgrade
|
| Advertising Expenses | - | 8.05 | 7.37 | 3.17 | 0.18 | 0.18 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.